NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.23. The biopharmaceutical company had revenue of $43.59 million for the quarter, compared to analysts' expectations of $43.30 million. Vanda Pharmaceuticals had a negative return on equity of 3.06% and a negative net margin of 2.84%. Vanda Pharmaceuticals's revenue was up 16.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.11) earnings per share. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Vanda Pharmaceuticals.

5 brokers have issued 12-month target prices for Vanda Pharmaceuticals' stock. Their predictions range from $18.00 to $27.00. On average, they expect Vanda Pharmaceuticals' share price to reach $22.40 in the next year. View Analyst Ratings for Vanda Pharmaceuticals.

Some companies that are related to Vanda Pharmaceuticals include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX) and ACADIA Pharmaceuticals (ACAD).

Press coverage about VNDA stock has been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.15 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 48.11 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Vanda Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.19%), venBio Select Advisor LLC (5.33%), Rothschild Asset Management Inc. (2.60%), Millennium Management LLC (1.91%), Prudential Financial Inc. (1.63%) and Northern Trust Corp (1.12%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., PNC Financial Services Group Inc., Millennium Management LLC, Spark Investment Management LLC, Cortina Asset Management LLC, Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

VNDA stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Hawk Ridge Capital Management LP, Alambic Investment Management L.P., Prudential Financial Inc., A.R.T. Advisors LLC, Russell Investments Group Ltd., UBS Group AG and Swiss National Bank. View Insider Buying and Selling for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $16.70.

Vanda Pharmaceuticals has a market capitalization of $885.88 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]